Can hydroxychloroquine and azithromycin combination cause cardiac rhythm disturbances in children with COVID-19 pneumonia?
Open Access
- 21 March 2025
- journal article
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 8 (2) , 308-312
Abstract
Aims: At the beginning of the COVID-19 pandemic; it has been shown that receiving hydroxychloroquine and azithromycin treatment decrease viral carriage of coronavirus in patients. In this study, we aimed to evaluate electrocardiography (ECG) abnormalities in pediatric patients with COVID-19 pneumonia receiving combined therapy with hydroxychloroquine and azithromycin. Methods: In this study; ECG and laboratory parameters of 24 children with COVID-19 pneumonia who were treated with hydroxychloroquine and azithromycin at Health Sciences University between June 2020 and November 2020 were analyzed retrospectively. P wave dispersion (PWd), QT interval (QT), QT dispersion (QTd), QTc interval (QTc), QTc dispersion (QTcd), Tpeak-Tend interval (Tp-e), Tp-e dispersion (Tp-ed), Tp-e/QT, Tp-Te/QTc ratios were evaluated with 12 lead ECG. ECG parameters and QTc interval were compared before and after (5 days) the treatment. Results: The mean age was 13±4.5 years and 62.5% were female. Median hospitalization length was 6 days. There was no statistically significant difference between the PWd, QT and QTc interval, QTd, QTcd, Tp-e interval, Tp-e dispersion, Tp-e/QT, Tp-e/QTd measurements and ratios of the before and after treatment. A significant difference was found for the decrease in hearth rate in regard to the measurement before and after the treatment. Conclusion: In our study, there were no rhythm problems which were observed on ECG in pediatric patients receiving hydroxychloroquine and azithromycin combination therapy for COVID-19 pneumonia. We also found that laboratory parameters were not specific for COVID-19 pneumonia in children.Keywords
This publication has 31 references indexed in Scilit:
- Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patientsInternational Journal of Antimicrobial Agents, 2021
- Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literatureInternational Journal of Antimicrobial Agents, 2021
- Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)JAMA Cardiology, 2020
- COVID-19 in 7780 pediatric patients: A systematic revieweClinicalMedicine, 2020
- Recommendations for the measurement of the QT interval during the use of drugs for COVID-19 infection treatment. Updatable in accordance with the availability of new evidenceJournal of Interventional Cardiac Electrophysiology, 2020
- Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcomeJournal of Pharmacokinetics and Pharmacodynamics, 2020
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, ChinaJAMA, 2020
- Hydroxychloroquine in children with interstitial (diffuse parenchymal) lung diseasesPediatric Pulmonology, 2014
- 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic featuresArthritis Care & Research, 2011
- Hydroxychloroquine: From Malaria to AutoimmunityClinical Reviews in Allergy & Immunology, 2011